"Viral Matrix Proteins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Proteins associated with the inner surface of the lipid bilayer of the viral envelope. These proteins have been implicated in control of viral transcription and may possibly serve as the "glue" that binds the nucleocapsid to the appropriate membrane site during viral budding from the host cell.
| Descriptor ID |
D014763
|
| MeSH Number(s) |
D12.776.964.970.880.940
|
| Concept/Terms |
Viral Matrix Proteins- Viral Matrix Proteins
- Matrix Proteins, Viral
- Proteins, Viral Matrix
- Membrane Proteins, Viral
- Viral M Proteins
- M Proteins, Viral
- Proteins, Viral M
- Viral Membrane Proteins
- Proteins, Viral Membrane
|
Below are MeSH descriptors whose meaning is more general than "Viral Matrix Proteins".
Below are MeSH descriptors whose meaning is more specific than "Viral Matrix Proteins".
This graph shows the total number of publications written about "Viral Matrix Proteins" by people in this website by year, and whether "Viral Matrix Proteins" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 0 | 1 | 1 |
| 2004 | 1 | 1 | 2 |
| 2006 | 1 | 0 | 1 |
| 2007 | 0 | 1 | 1 |
| 2013 | 1 | 0 | 1 |
| 2014 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Viral Matrix Proteins" by people in Profiles.
-
Ngo MC, Ando J, Leen AM, Ennamuri S, Lapteva N, Vera JF, Min-Venditti A, Mims MP, Heslop HE, Bollard CM, Gottschalk S, Rooney CM. Complementation of antigen-presenting cells to generate T lymphocytes with broad target specificity. J Immunother. 2014 May; 37(4):193-203.
-
Bollard CM, Gottschalk S, Torrano V, Diouf O, Ku S, Hazrat Y, Carrum G, Ramos C, Fayad L, Shpall EJ, Pro B, Liu H, Wu MF, Lee D, Sheehan AM, Zu Y, Gee AP, Brenner MK, Heslop HE, Rooney CM. Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins. J Clin Oncol. 2014 Mar 10; 32(8):798-808.
-
Li J, Mookerjee B, Wagner J, Flomenberg N. In vitro methods for generating highly purified EBV associated tumor antigen-specific T cells by using solid phase T cell selection system for immunotherapy. J Immunol Methods. 2007 Dec 01; 328(1-2):169-81.
-
Harcourt GC, Scriba TJ, Semmo N, Bounds S, Taylor E, Klenerman P. Identification of key peptide-specific CD4+ T cell responses to human cytomegalovirus: implications for tracking antiviral populations. Clin Exp Immunol. 2006 Nov; 146(2):203-10.
-
Lee JM, Lee KH, Farrell CJ, Ling PD, Kempkes B, Park JH, Hayward SD. EBNA2 is required for protection of latently Epstein-Barr virus-infected B cells against specific apoptotic stimuli. J Virol. 2004 Nov; 78(22):12694-7.
-
D'Souza BN, Edelstein LC, Pegman PM, Smith SM, Loughran ST, Clarke A, Mehl A, Rowe M, G?linas C, Walls D. Nuclear factor kappa B-dependent activation of the antiapoptotic bfl-1 gene by the Epstein-Barr virus latent membrane protein 1 and activated CD40 receptor. J Virol. 2004 Feb; 78(4):1800-16.
-
Lucas KG, Sun Q, Burton RL, Tilden A, Vaughan WP, Carabasi M, Salzman D, Ship A. A phase I-II trial to examine the toxicity of CMV- and EBV-specific cytotoxic T lymphocytes when used for prophylaxis against EBV and CMV disease in recipients of CD34-selected/T cell-depleted stem cell transplants. Hum Gene Ther. 2000 Jul 01; 11(10):1453-63.